A U.S. appeals court upheld a ruling that canceled patents owned by Teva Pharmaceutical Industries Ltd. on the blockbuster multiple sclerosis drug Copaxone.
Bristol-Myers Squibb’s blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.
AbbVie Inc. settled all patent disputes with Novartis AG, granting the Swiss drugmaker a non-exclusive license to manufacture and sell a copycat version of the blockbuster drug Humira.
A New Jersey jury cleared J&J of liability in a case involving a woman who alleged that the company’s talc-based products, including baby powder, contain asbestos and caused her cancer.
Pfizer Inc. settled charges by New York’s attorney general that the company misled consumers in a drug copayment coupon program into thinking they would pay far less to fill prescriptions than they ended up having to shell out.
Walgreens Boots Alliance Inc. came up short of analysts’ estimates for quarterly revenue, as sales of personal-care products and over-the-counter drugs fell both in the U.S. drugstore operator’s home market and UK-based Boots chain.
Bristol-Myers Squibb and Israel’s Compugen will collaborate in clinical trials for patients with advanced solid tumors.
An advisory panel to the U.S. Food and Drug Administration voted unanimously in favor of Celltrion Pharm Inc.’s copycat drug of Roche Holding AG’s blood cancer drug Rituxan.
Pharmacy chain CVS Health Corp. won U.S. antitrust approval for the $69 billion acquisition of health insurer Aetna Inc., the Justice Department said.
AcelRx Pharmaceuticals Inc.’s opioid painkiller offers no apparent advantage to currently available therapies, staff reviewers of the U.S. Food and Administration said.
Mental health disorders are on the rise in every country in the world and could cost the global economy up to $16 trillion between 2010 and 2030 if a collective failure to respond is not addressed, according to an expert report.
The number of new clinical trials started in Britain during 2017 was 25 percent lower than the average for 2009-2016, as anxiety about Brexit’s impact on future medicines regulation made companies hesitate about running studies in the country.
Trevena Inc.’s opioid injection to treat acute pain could be abused and potentially lead to overdose, staff reviewers of the U.S. FDA said, sending the drugmaker’s shares down 66 percent.
Johnson & Johnson said the company’s blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.
Affimed N.V. put on hold the testing of the drug developer’s experimental cancer drug following the death of a patient and two life-threatening events.
Bausch Health, formerly Valeant Pharmaceuticals, received tentative U.S. approval to market the plaque psoriasis lotion Bryhali.
The U.S. Food and Drug Administration approved Akcea Therapeutics’ rare genetic disease drug Tegsedi, which was developed along with Ionis Pharmaceuticals.
The EMA’s risk assessment committee recommended restrictions on the use of the broad-spectrum antibiotics.
Vitamin D supplementation may not improve bone density or prevent fractures and falls in adults, a large new analysis suggests.
U.S. regulators approved expanded use of Roche’s drug Hemlibra to include almost all patients with hemophilia A.